The proton pump inhibitors market offers a range of medications that help reduce stomach acid production. Prescription proton pump inhibitors are effective in treating conditions where excess stomach acid is present, such as acid reflux, stomach ulcers, and heartburn. They provide quick and long-lasting relief from frequent acid reflux symptoms. The global rise in gastrointestinal issues like acidity, heartburn, and ulcers is driving significant demand for PPI drugs.
The Global Proton Pump Inhibitors Market is estimated to be valued at US$ 3.8 Mn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the proton pump inhibitors are Horizon Therapeutics plc, Ammonett Pharma LLC, Medison Pharma Ltd., Modern Dietetics Inc., Synageva BioPharma Corp., Medison Pharma Ltd., Swedish Orphan Biovitrum AB (Sobi), Entera Health, Inc., Dipharma Francis S.r.l., Ucyclyd Pharma, Inc. These companies hold a majority market share and are focusing on developing innovative drug formulations and delivery methods.
The growing population diagnosed with gastric issues like GERD and ulcers present lucrative growth opportunities. Market players are investing in R&D to expand the therapeutic applications of PPIs.
Globally, the prevalence of lifestyle diseases is increasing rapidly in developing nations. Key companies are looking at these emerging markets for expansion opportunities. Partnerships with local players help increase geographical presence and access to new customer segments.
Market drivers – The rising geriatric population prone to gastrointestinal disorders coupled with growing awareness about proton pump inhibitors drives the market growth. Changing lifestyles leading to stress and unhealthy diets have contributed to a spike in acid reflux diseases.
Market restraints – Patent expirations of popular PPI drug brands enable generic competition, posing a challenge. Strict regulatory norms for new drug approvals and adverse drug reactions associated with long-term PPI usage also limit market potential. High treatment costs in some nations restrict widespread adoption of PPI medications.
Segment Analysis
The Proton Pump Inhibitors Market Demand is dominated by the esomeprazole sub segment. Esomeprazole accounts for around 60% of the total market owing to its superior efficacy in treating conditions like gastroesophageal reflux disease and peptic ulcers. It has minimal adverse effects compared to other proton pump inhibitors, making it a preferred choice for both clinicians and patients. The pantoprazole sub segment follows esomeprazole in terms of market share due to its effectiveness and longer duration of action.
Global Analysis
The North American region accounts for over 40% of the global proton pump inhibitors market. This is attributed to the high prevalence of acid reflux disorders and availability of advanced healthcare facilities in countries like the US and Canada. However, the Asia Pacific region is witnessing the fastest growth and is projected to surpass North America in the coming years. Factors such as rising affordability, growing awareness among public regarding acid reflux management, and increasing healthcare expenditure are contributing to the growth of the market in Asia Pacific countries like China, India and Japan. Additionally, the presence of major generic manufacturers in India and China is also augmenting the regional market growth.
Get more insights, On Proton Pump Inhibitors Market
Comments
0 comment